Key result
New-generation DESs linked to ~43% lower 5-year mortality versus BMSs.
Why the study?
Drug-eluting stents are preferred for MI but are not reimbursed under some national health insurance systems, creating economic barriers, and cost-effectiveness data for new-generation DESs compared to bare-metal stents were limited.
Are new-generation drug-eluting stents cost-effective in reducing 1-, 2-, and 5-year mortality compared with bare-metal stents in patients with myocardial infarction?
Cohort (n=10,672)
Yes
Are new-generation drug-eluting stents cost-effective in reducing 1-, 2-, and 5-year mortality compared with bare-metal stents in patients with myocardial infarction?
Answers are grounded in this paper and cite their sources.
In a nationwide Taiwanese cohort of MI patients, new-generation drug-eluting stents significantly reduced 1-, 2-, and 5-year mortality compared with bare-metal stents and were cost-effective under WHO thresholds, supporting national health insurance reimbursement.
Background Drug-eluting stents (DESs) are the preferred treatment for myocardial infarction (MI) but are not reimbursed under some national health insurance (NHI) systems. Therefore, those who care about long-term effectiveness might face economic limitations when selecting DESs. Moreover, limited information is available concerning the cost-effectiveness analysis of new-generation (including second- and third-generation) DESs. We used nationwide population-based data to evaluate the cost-effectiveness of new-generation DESs compared to bare-metal stents (BMSs) from the NHI perspective. Methods We included all 10,672 MI patients who underwent stent implantation in 2018 in Taiwan and were followed to 2023 through Taiwan’s NHI database. After 1:1 propensity score matching, 3,913 patients were in each BMS and DES group. Multivariable Cox and linear regression models were performed to evaluate the effect of DES use on 1-, 2-, and 5-year mortality and medical cost, respectively. Then, the incremental cost-effectiveness ratios (ICERs) were calculated. Results Patients receiving DESs had 52%, 48%, and 43% lower risks of 1-, 2-, and 5-year mortality and NT$27,839 higher 1-year costs compared to those receiving BMSs, respectively. The 1-, 2-, and 5-year ICERs for DESs were NT$463,983, NT$241,299, and NT$302,750 per death avoided, respectively. Conclusions New-generation DESs are cost-effective based on the cost-effectiveness threshold recommended by the World Health Organization. Considering the effectiveness and cost of new-generation DESs, including reimbursement for this technology under the NHI system would benefit beneficiaries and enhance long-term survival for MI.
No takes yet. Share an insight, caveat, or question.
Tung et al. (2026) conducted a cohort in Myocardial infarction undergoing stent implantation (n=10,672). New-generation (second- and third-generation) drug-eluting stents vs. Bare-metal stents was evaluated on 1-, 2-, and 5-year mortality and incremental cost-effectiveness ratios (ICERs) (43% lower risk of 5-year mortality (52% at 1-year, 48% at 2-year)). New-generation DESs reduced 1-, 2-, and 5-year mortality risks by 52%, 48%, and 43% versus BMSs, with a 5-year ICER of NT$302,750 per death avoided.
Synapse has enriched 10 related papers. Consider them for comparative context: